We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetic Analysis of Liver Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00768001
Recruitment Status : Terminated (low accrual)
First Posted : October 7, 2008
Last Update Posted : February 1, 2012
Sponsor:
Information provided by (Responsible Party):
Samuel So, Stanford University

Brief Summary:
Liver cancer is a leading cause of cancer deaths worldwide. While the molecular pathogenesis of liver cancer has been extensively studied, less is known about how the molecular biology of liver cancer influences clinical outcome and treatment response. We are developing a translational research program that will characterize molecular changes in liver cancer. We plan to use molecular information obtained from studying liver tumor tissues to develop new diagnostics and treatment regimens for patients with these cancers. The experimental approach will require freezing fresh tumor tissues obtained from surgical procedures, which will be subsequently used for analysis of DNA, protein and mRNA expression. Many patients with liver cancer are referred to the Stanford Liver Tumor Board for consultation and treatment recommendations. We propose to gather tissue samples from those who subsequently undergo biopsy, liver resection surgery, or transplant surgery.

Condition or disease
Liver Cancer Hepatitis B Hepatitis C Hepatobiliary Cancers Hepatobiliary Cancers Liver

Study Type : Observational
Actual Enrollment : 41 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genetic Analysis of Liver Cancer
Study Start Date : June 2008
Primary Completion Date : October 2011
Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Biospecimen Retention:   Samples With DNA
tumor sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
liver cancer patients
Criteria

Inclusion Criteria:3.1.1 Male or female patients 18 years of age and above. 3.1.2 Patients diagnosed with liver cancer based on biopsy or serum alpha-fetoprotein level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. Patients with metastatic tumor from anther organ, such as metastatic colon cancer.

3.13 Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:3.2.1Female patients who are pregnant or nursing will be excluded from the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00768001


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Samuel So
Investigators
Principal Investigator: Samuel So Stanford University

Responsible Party: Samuel So, Professor of Medicine, Stanford University
ClinicalTrials.gov Identifier: NCT00768001     History of Changes
Other Study ID Numbers: HEP0012
98717 ( Other Identifier: SU )
First Posted: October 7, 2008    Key Record Dates
Last Update Posted: February 1, 2012
Last Verified: January 2012

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis B
Liver Neoplasms
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepadnaviridae Infections
DNA Virus Infections
Digestive System Neoplasms
Neoplasms by Site
Neoplasms